{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T19:22:01Z","timestamp":1769887321160,"version":"3.49.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T00:00:00Z","timestamp":1756339200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T00:00:00Z","timestamp":1756339200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Association Jules Bordet","award":["2016-15"],"award-info":[{"award-number":["2016-15"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s00259-025-07500-y","type":"journal-article","created":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T02:45:29Z","timestamp":1756349129000},"page":"1521-1531","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The SCARLET trial: a prospective phase II study of somatostatin receptor imaging for potential radiotheranostic application in patients with relapsing and refractory multiple myeloma"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6674-9493","authenticated-orcid":false,"given":"Wendy","family":"Delbart","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ioannis","family":"Karfis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"Vercruyssen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roland","family":"De Wind","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathalie","family":"Meuleman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Z\u00e9na","family":"Wimana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Flamen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erwin","family":"Woff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,28]]},"reference":[{"key":"7500_CR1","doi-asserted-by":"publisher","first-page":"129","DOI":"10.3390\/cancers14010129","volume":"14","author":"N Ahmadi Bidakhvidi","year":"2021","unstructured":"Ahmadi Bidakhvidi N, Goffin K, Dekervel J, Baete K, Nackaerts K, Clement P, et al. Peptide receptor radionuclide therapy targeting the somatostatin receptor: basic principles, clinical applications and optimization strategies. Cancers (Basel). 2021;14:129.","journal-title":"Cancers (Basel)"},{"key":"7500_CR2","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa1607427","volume":"376","author":"J Strosberg","year":"2017","unstructured":"Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376:125\u201335.","journal-title":"N Engl J Med"},{"key":"7500_CR3","doi-asserted-by":"publisher","first-page":"2578","DOI":"10.1200\/JCO.2018.78.5865","volume":"36","author":"J Strosberg","year":"2018","unstructured":"Strosberg J, Wolin E, Chasen B, Kulke M, Bushnell D, Caplin M, et al. Health-Related quality of life in patients with progressive midgut neuroendocrine tumors treated with 177Lu-Dotatate in the phase III NETTER-1 trial. J Clin Oncol Off J Am Soc Clin Oncol. 2018;36:2578\u201384.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"7500_CR4","doi-asserted-by":"publisher","DOI":"10.1111\/jne.13343","volume":"35","author":"B Kos-Kud\u0142a","year":"2023","unstructured":"Kos-Kud\u0142a B, Casta\u00f1o JP, Denecke T, Grande E, Kjaer A, Koumarianou A, et al. European neuroendocrine tumour society (ENETS) 2023 guidance paper for nonfunctioning pancreatic neuroendocrine tumours. J Neuroendocrinol. 2023;35: e13343.","journal-title":"J Neuroendocrinol"},{"key":"7500_CR5","doi-asserted-by":"publisher","DOI":"10.1111\/jne.13423","volume":"36","author":"A Lamarca","year":"2024","unstructured":"Lamarca A, Bartsch DK, Caplin M, Kos-Kudla B, Kjaer A, Partelli S, et al. European neuroendocrine tumor society (ENETS) 2024 guidance paper for the management of well-differentiated small intestine neuroendocrine tumours. J Neuroendocrinol. 2024;36: e13423.","journal-title":"J Neuroendocrinol"},{"key":"7500_CR6","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Lutetium-177\u2013PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385:1091\u2013103.","journal-title":"N Engl J Med"},{"key":"7500_CR7","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1053\/j.seminoncol.2016.11.004","volume":"43","author":"D Kazandjian","year":"2016","unstructured":"Kazandjian D. Multiple myeloma epidemiology and survival: a unique malignancy. Semin Oncol. 2016;43:676\u201381.","journal-title":"Semin Oncol"},{"key":"7500_CR8","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1056\/NEJMra030831","volume":"350","author":"GD Roodman","year":"2004","unstructured":"Roodman GD. Mechanisms of bone metastasis. N Engl J Med. 2004;350:1655\u201364.","journal-title":"N Engl J Med"},{"key":"7500_CR9","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41408-022-00643-3","volume":"12","author":"J Blad\u00e9","year":"2022","unstructured":"Blad\u00e9 J, Beksac M, Caers J, Jurczyszyn A, von Lilienfeld-Toal M, Moreau P, et al. Extramedullary disease in multiple myeloma: a systematic literature review. Blood Cancer J. 2022;12:45.","journal-title":"Blood Cancer J"},{"key":"7500_CR10","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1111\/bjh.17338","volume":"194","author":"L Rosi\u00f1ol","year":"2021","unstructured":"Rosi\u00f1ol L, Beksac M, Zamagni E, Van de Donk NWCJ, Anderson KC, Badros A, et al. Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations. Br J Haematol. 2021;194:496\u2013507.","journal-title":"Br J Haematol"},{"key":"7500_CR11","doi-asserted-by":"publisher","first-page":"e206","DOI":"10.1016\/S1470-2045(17)30189-4","volume":"18","author":"M Cavo","year":"2017","unstructured":"Cavo M, Terpos E, Nanni C, Moreau P, Lentzsch S, Zweegman S, et al. Role of 18F-FDG PET\/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the international myeloma working group. Lancet Oncol. 2017;18:e206\u201317.","journal-title":"Lancet Oncol"},{"key":"7500_CR12","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s00259-024-06858-9","volume":"52","author":"C Nanni","year":"2024","unstructured":"Nanni C, Deroose CM, Balogova S, Lapa C, Withofs N, Subesinghe M, et al. EANM guidelines on the use of [18F]FDG PET\/CT in diagnosis, staging, prognostication, therapy assessment, and restaging of plasma cell disorders. Eur J Nucl Med Mol Imaging. 2024;52:171\u201392.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"7500_CR13","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1053\/j.semnuclmed.2022.10.008","volume":"53","author":"D Bezzi","year":"2023","unstructured":"Bezzi D, Ambrosini V, Nanni C. Clinical value of FDG-PET\/CT in multiple myeloma: an update. Semin Nucl Med. 2023;53(3):352\u201370.","journal-title":"Semin Nucl Med"},{"key":"7500_CR14","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1007\/s00259-019-04312-9","volume":"46","author":"Y Abe","year":"2019","unstructured":"Abe Y, Ikeda S, Kitadate A, Narita K, Kobayashi H, Miura D, et al. Low hexokinase-2 expression-associated false-negative 18F-FDG PET\/CT as a potential prognostic predictor in patients with multiple myeloma. Eur J Nucl Med Mol Imaging. 2019;46:1345\u201350.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7500_CR15","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1182\/blood-2017-03-774422","volume":"130","author":"L Rasche","year":"2017","unstructured":"Rasche L, Angtuaco E, McDonald JE, Buros A, Stein C, Pawlyn C, et al. Low expression of hexokinase-2 is associated with false-negative FDG-positron emission tomography in multiple myeloma. Blood. 2017;130:30\u20134.","journal-title":"Blood"},{"key":"7500_CR16","doi-asserted-by":"publisher","unstructured":"von Hinten J, Kircher M, Dierks A, Pfob CH, Higuchi T, Pomper MG et al. Molecular Imaging in Multiple Myeloma\u2014Novel PET Radiotracers Improve Patient Management and Guide Therapy. Front Nucl Med [Internet]. 2022 [cited 2024 Nov 9];2. Available from: https:\/\/www.frontiersin.org\/journals\/nuclear-medicine\/articles\/https:\/\/doi.org\/10.3389\/fnume.2022.801792\/full","DOI":"10.3389\/fnume.2022.801792\/full"},{"key":"7500_CR17","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.7150\/thno.19050","volume":"7","author":"C Lapa","year":"2017","unstructured":"Lapa C, Herrmann K, Schirbel A, H\u00e4nscheid H, L\u00fcckerath K, Schottelius M, et al. CXCR4-directed endoradiotherapy induces high response rates in extramedullary relapsed multiple myeloma. Theranostics. 2017;7:1589\u201397.","journal-title":"Theranostics"},{"key":"7500_CR18","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.nucmedbio.2021.03.006","volume":"96\u201397","author":"W Delbart","year":"2021","unstructured":"Delbart W, Ghanem GE, Karfis I, Flamen P, Wimana Z. Investigating intrinsic radiosensitivity biomarkers to peptide receptor radionuclide therapy with [177Lu]Lu-DOTATATE in a panel of cancer cell lines. Nucl Med Biol. 2021;96\u201397:68\u201379.","journal-title":"Nucl Med Biol"},{"key":"7500_CR19","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1182\/blood.V93.5.1724","volume":"93","author":"P Georgii-Hemming","year":"1999","unstructured":"Georgii-Hemming P, Str\u00f6mberg T, Janson ET, Stridsberg M, Wiklund HJ, Nilsson K. The somatostatin analog octreotide inhibits growth of interleukin-6 (IL-6)-dependent and IL-6-independent human multiple myeloma cell lines. Blood. 1999;93:1724\u201331.","journal-title":"Blood"},{"key":"7500_CR20","first-page":"77","volume":"28","author":"C Kerros","year":"2009","unstructured":"Kerros C, Cavey T, Sola B, Jauzac P, Allouche S. Somatostatin and opioid receptors do not regulate proliferation or apoptosis of the human multiple myeloma U266 cells. J Exp Clin Cancer Res CR. 2009;28:77.","journal-title":"J Exp Clin Cancer Res CR"},{"key":"7500_CR21","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1097\/RLU.0b013e31828e9722","volume":"39","author":"P Sharma","year":"2014","unstructured":"Sharma P, Dhull VS, Suman SKC, Bal C, Malhotra A, Kumar R. 68Ga-DOTANOC somatostatin receptor PET-CT imaging in multiple myeloma. Clin Nucl Med. 2014;39:374\u20135.","journal-title":"Clin Nucl Med"},{"key":"7500_CR22","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1007\/s00259-009-1199-5","volume":"37","author":"A Agool","year":"2010","unstructured":"Agool A, Slart RHJA, Dierckx RAJO, Kluin PM, Visser L, Jager PL, et al. Somatostatin receptor scintigraphy might be useful for detecting skeleton abnormalities in patients with multiple myeloma and plasmacytoma. Eur J Nucl Med Mol Imaging. 2010;37:124\u201330.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7500_CR23","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1097\/MNM.0000000000000610","volume":"38","author":"K Sonmezoglu","year":"2017","unstructured":"Sonmezoglu K, Vatankulu B, Elverdi T, Akyel R, Erkan ME, Halac M, et al. The role of 68Ga-DOTA-TATE PET\/CT scanning in the evaluation of patients with multiple myeloma: preliminary results. Nucl Med Commun. 2017;38:76\u201383.","journal-title":"Nucl Med Commun"},{"key":"7500_CR24","doi-asserted-by":"publisher","first-page":"2554","DOI":"10.1038\/s41375-024-02404-6","volume":"38","author":"M-V Mateos","year":"2024","unstructured":"Mateos M-V, Weisel K, De Stefano V, Goldschmidt H, Delforge M, Mohty M, et al. LocoMMotion: a study of real-life current standards of care in triple-class exposed patients with relapsed\/refractory multiple myeloma \u2013 2-year follow-up (final analysis). Leukemia. 2024;38:2554\u201360.","journal-title":"Leukemia"},{"key":"7500_CR25","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1002\/ajh.26590","volume":"97","author":"SV Rajkumar","year":"2022","unstructured":"Rajkumar SV, Multiple M. 2022 update on diagnosis, Risk-stratification and management. Am J Hematol. 2022;97:1086\u2013107.","journal-title":"Am J Hematol"},{"key":"7500_CR26","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1007\/s00259-014-2961-x","volume":"42","author":"R Boellaard","year":"2015","unstructured":"Boellaard R, Delgado-Bolton R, Oyen WJG, Giammarile F, Tatsch K, Eschner W, et al. FDG PET\/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42:328\u201354.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7500_CR27","first-page":"204","volume":"64","author":"TA Hope","year":"2023","unstructured":"Hope TA, Allen-Auerbach M, Bodei L, Calais J, Dahlbom M, Dunnwald LK, et al. SNMMI procedure standard\/eanm practice guideline for SSTR PET: imaging neuroendocrine tumors. J Nucl Med Off Publ Soc Nucl Med. 2023;64:204\u201310.","journal-title":"J Nucl Med Off Publ Soc Nucl Med"},{"key":"7500_CR28","unstructured":"European Directorate for the Quality of Medicines. & HealthCare (EDQM). Ph Eur 11.0, 2482 (01\/2022)."},{"key":"7500_CR29","doi-asserted-by":"publisher","DOI":"10.1111\/jne.13474","volume":"37","author":"M Di Franco","year":"2025","unstructured":"Di Franco M, Fortunati E, Zanoni L, Fanti S, Ambrosini V. The role of combined FDG and SST PET\/CT in neuroendocrine tumors. J Neuroendocrinol. 2025;37: e13474.","journal-title":"J Neuroendocrinol"},{"key":"7500_CR30","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.2967\/jnumed.123.266956","volume":"65","author":"S Severi","year":"2024","unstructured":"Severi S, Grassi I, Bongiovanni A, Nicolini S, Marini I, Arpa D, et al. Peptide receptor radionuclide therapy in advanced refractory meningiomas: efficacy and toxicity in a long follow-up. J Nucl Med. 2024;65:1409\u201315.","journal-title":"J Nucl Med"},{"key":"7500_CR31","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1158\/1078-0432.CCR-23-2533","volume":"30","author":"SC Kurz","year":"2024","unstructured":"Kurz SC, Zan E, Cordova C, Troxel AB, Barbaro M, Silverman JS, et al. Evaluation of the SSTR2-targeted radiopharmaceutical 177Lu-DOTATATE and SSTR2-specific 68Ga-DOTATATE PET as imaging biomarker in patients with intracranial meningioma. Clin Cancer Res Off J Am Assoc Cancer Res. 2024;30:680\u20136.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"7500_CR32","doi-asserted-by":"publisher","first-page":"22","DOI":"10.2967\/jnmt.122.264904","volume":"51","author":"E Askari","year":"2023","unstructured":"Askari E, Moghadam SZ, Wild D, Delpassand E, Baldari S, Nilica B, et al. Peptide receptor radionuclide therapy in Merkel cell carcinoma: a comprehensive review. J Nucl Med Technol. 2023;51:22\u20135.","journal-title":"J Nucl Med Technol"},{"key":"7500_CR33","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1097\/RLU.0000000000004539","volume":"48","author":"Q Liu","year":"2023","unstructured":"Liu Q, Kulkarni HR, Zhao T, Schuchardt C, Chen X, Zhu Z, et al. Peptide receptor radionuclide therapy in patients with advanced progressive medullary thyroid cancer: efficacy, safety, and survival predictors. Clin Nucl Med. 2023;48:221\u20137.","journal-title":"Clin Nucl Med"},{"key":"7500_CR34","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2023.2281657","volume":"55","author":"J Wang","year":"2023","unstructured":"Wang J, Shen N, Shen X, Zhang R, Jin Y, Li J, et al. Survival trends and prognostic factors of patients with newly diagnosed multiple myeloma accompanied with extramedullary disease. Ann Med. 2023;55: 2281657.","journal-title":"Ann Med"},{"key":"7500_CR35","doi-asserted-by":"publisher","first-page":"2432","DOI":"10.1007\/s00259-023-06214-3","volume":"50","author":"SPM Souza","year":"2023","unstructured":"Souza SPM, Frasson FC, Takahashi MES, Duarte GBO, Castro VP, Pericole FV, et al. Head-to-head comparison of [68Ga]Ga-PSMA-11 and [18F]FDG PET\/CT in multiple myeloma. Eur J Nucl Med Mol Imaging. 2023;50:2432\u201340.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7500_CR36","first-page":"236","volume":"65","author":"M Mileva","year":"2024","unstructured":"Mileva M, Marin G, Levillain H, Artigas C, Van Bogaert C, Marin C, et al. Prediction of 177Lu-DOTATATE PRRT outcome using multimodality imaging in patients with gastroenteropancreatic neuroendocrine tumors: results from a prospective phase II LUMEN study. J Nucl Med Off Publ Soc Nucl Med. 2024;65:236\u201344.","journal-title":"J Nucl Med Off Publ Soc Nucl Med"},{"key":"7500_CR37","doi-asserted-by":"crossref","unstructured":"Hill RP. The changing paradigm of tumour response to irradiation. Br J Radiol [Internet]. 2017;90. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC5605022\/","DOI":"10.1259\/bjr.20160474"},{"key":"7500_CR38","first-page":"248","volume":"57","author":"K Herrmann","year":"2016","unstructured":"Herrmann K, Schottelius M, Lapa C, Osl T, Poschenrieder A, H\u00e4nscheid H, et al. First-in-Human experience of CXCR4-Directed endoradiotherapy with 177Lu- and 90Y-Labeled pentixather in Advanced-Stage multiple myeloma with extensive Intra- and extramedullary disease. J Nucl Med Off Publ Soc Nucl Med. 2016;57:248\u201351.","journal-title":"J Nucl Med Off Publ Soc Nucl Med"},{"key":"7500_CR39","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.3390\/cancers13061285","volume":"13","author":"A Schavgoulidze","year":"2021","unstructured":"Schavgoulidze A, Cazaubiel T, Perrot A, Avet-Loiseau H, Corre J. Multiple myeloma: heterogeneous in every way. Cancers. 2021;13:1285.","journal-title":"Cancers"},{"key":"7500_CR40","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1038\/s41467-017-00296-y","volume":"8","author":"L Rasche","year":"2017","unstructured":"Rasche L, Chavan SS, Stephens OW, Patel PH, Tytarenko R, Ashby C, et al. Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing. Nat Commun. 2017;8:268.","journal-title":"Nat Commun"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07500-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-025-07500-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07500-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T04:43:07Z","timestamp":1769834587000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-025-07500-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,28]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["7500"],"URL":"https:\/\/doi.org\/10.1007\/s00259-025-07500-y","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,28]]},"assertion":[{"value":"10 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in the study were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This study was approved by the Jules Bordet Institute Ethics Committee (CE3090). Written informed consent was obtained from all study participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}